MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Objectives To provide an integrated analysis of major adverse cardiovascular events (MACEs) and events of venous thromboembolism (VTE) and associated risk factors across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) phase 2b/3 upadacitinib clinical programmes....

Full description

Bibliographic Details
Main Authors: Peter Nash, Iain B McInnes, Ernest Choy, Jeffrey R Curtis, Eduardo Mysler, Christina Charles-Schoeman, Nasser Khan, Kunihiro Yamaoka, Ralph Lippe, Hannah Palac, Anna K Shmagel, Jessica Suboticki
Format: Article
Language:English
Published: BMJ Publishing Group 2023-10-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/9/4/e003392.full

Internet

https://rmdopen.bmj.com/content/9/4/e003392.full

Similar Items